Pharmaceutical preparations comprising human proNGF

US8318671B1 · kind B1 · utility

Assignee

• Scil Proteins GmbH · DE

Inventors

• Anke Rattenholl · Bodenwerder, DE
• Adelbert Grossmann · Murnau am Staffelsee, DE
• Elisabeth Schwarz · Bodenwerder, DE
• Rainer Rudolph · Waldshut-Tiengen, DE

Key dates

• Filing date: Oct 11, 1999
• Grant date: Nov 27, 2012
• Expiry date: Sep 10, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a method for producing biologically active β-NGF from the proform proNGF. After expressing the proform of the β-NGF in a prokaryotic host cell, the recombinant protein is isolated in the form of insoluble inactive aggregates (inclusion bodies). After the solubilization thereof in a strong denaturing agent and the subsequent conversion thereof into the natural conformation, which is determined by the disulfide bridges present in the natural β-NGF, biologically active β-NGF is obtained by subsequently splitting-off the prosequence.